Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO). (Q39146320)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 November 2016

Language	Label	Description	Also known as
English	Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).	scientific article published on 29 November 2016

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO) (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

0 references

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Jose Luis Calleja-Panero

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Manuel Romero-Gomez

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

author name string

M Buti

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

M Diago

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

E Ortega

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

R Planas

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

F G Rodríguez

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

J M Pascasio

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

B Fevery

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

D Kurland

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

C Corbett

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

R Kalmeijer

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

W Jessner

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

language of work or name

0 references

publication date

29 November 2016

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

45

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

468-475

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

Management of hepatitis C infection before and after liver transplantation

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

Hepatitis C genotype 4: What we know and what we don't yet know.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

Hepatitis C virus genotype 4 therapy: progress and challenges.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

EASL Recommendations on Treatment of Hepatitis C 2015

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13883

21 January 2018

Identifiers

10.1111/APT.13883

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27896822%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39146320&oldid=1562842267"